Nutritional risks emerge as GLP-1 therapies gain popularity for diabetes and obesity treatment

As GLP-1 medications like semaglutide and tirzepatide become central to managing type 2 diabetes and obesity, concerns grow over potential nutritional gaps and loss of lean muscle and bone mass, calling for comprehensive dietary and exercise strategies. GLP-1 drugs such…















